Liquidity ratios measure the company ability to meet its short-term obligations.
Paying user area
Try for free
AbbVie Inc. pages available for free this week:
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to AbbVie Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Liquidity Ratios (Summary)
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Current ratio | ||||||
| Quick ratio | ||||||
| Cash ratio |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
The liquidity position, as indicated by the presented ratios, demonstrates a generally declining trend over the five-year period. While initial values suggest a moderate level of liquidity, subsequent years reveal a weakening ability to meet short-term obligations using readily available assets.
- Current Ratio
- The current ratio experienced an initial improvement from 0.79 in 2021 to 0.96 in 2022. However, this was followed by a consistent decline, reaching 0.66 in 2024 and remaining relatively stable at 0.67 in 2025. This suggests a decreasing capacity to cover current liabilities with current assets.
- Quick Ratio
- Similar to the current ratio, the quick ratio increased from 0.56 in 2021 to 0.69 in 2022. A subsequent downward trend is observed, with the ratio falling to 0.43 in 2024 and 0.41 in 2025. This indicates a diminishing ability to meet short-term liabilities with the most liquid assets, excluding inventory.
- Cash Ratio
- The cash ratio exhibited a gradual increase from 0.28 in 2021 to 0.34 in 2023. However, a significant decrease is apparent in the later years, dropping to 0.14 in 2024 and further to 0.12 in 2025. This signifies a substantial reduction in the proportion of current assets held as cash and cash equivalents, and a corresponding decrease in the immediate ability to satisfy current obligations.
Collectively, the trends across all three ratios point to a weakening liquidity profile. The declines observed in 2024 and 2025 are particularly noteworthy, suggesting a potential increase in liquidity risk during those periods. Further investigation into the underlying drivers of these changes, such as shifts in working capital management or changes in debt structure, would be warranted.
Current Ratio
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Current assets | ||||||
| Current liabilities | ||||||
| Liquidity Ratio | ||||||
| Current ratio1 | ||||||
| Benchmarks | ||||||
| Current Ratio, Competitors2 | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Current Ratio, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Current Ratio, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Current ratio = Current assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The current ratio exhibited fluctuations over the five-year period. Initially, the ratio increased before declining and stabilizing at a lower level. A review of the underlying components, current assets and current liabilities, provides further insight into these movements.
- Overall Trend
- The current ratio began at 0.79 in 2021, increased to 0.96 in 2022, then decreased to 0.87 in 2023. A more pronounced decline occurred in 2024, falling to 0.66, and remained relatively stable at 0.67 in 2025.
- Current Assets
- Current assets increased from US$27,928 million in 2021 to US$28,463 million in 2022, representing a modest increase. A more substantial rise was observed in 2023, reaching US$33,002 million. However, current assets decreased significantly in 2024 to US$25,582 million, and showed a partial recovery to US$29,062 million in 2025.
- Current Liabilities
- Current liabilities decreased considerably from US$35,194 million in 2021 to US$29,538 million in 2022. They then increased to US$37,841 million in 2023, and continued to rise in subsequent years, reaching US$38,749 million in 2024 and US$43,289 million in 2025.
- Ratio Dynamics
- The initial improvement in the current ratio from 2021 to 2022 was driven by a larger decrease in current liabilities than the increase in current assets. The subsequent decline in the ratio from 2022 onwards is attributable to the combination of decreasing current assets, particularly in 2024, and increasing current liabilities throughout the period. The stabilization in 2025 suggests a potential leveling off of these opposing forces.
The observed trend indicates a weakening in the company’s ability to cover its short-term obligations with its short-term assets, particularly in the later years of the period. Continued monitoring of these components is warranted.
Quick Ratio
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Cash and equivalents | ||||||
| Short-term investments | ||||||
| Accounts receivable, net | ||||||
| Total quick assets | ||||||
| Current liabilities | ||||||
| Liquidity Ratio | ||||||
| Quick ratio1 | ||||||
| Benchmarks | ||||||
| Quick Ratio, Competitors2 | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Quick Ratio, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Quick Ratio, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The quick ratio exhibited fluctuating performance over the five-year period. Initial increases were followed by declines, indicating shifts in the company’s short-term liquidity position.
- Overall Trend
- The quick ratio began at 0.56 in 2021, increased to a peak of 0.69 in 2022, then decreased consistently to 0.41 in 2025. This suggests an initial improvement in the ability to meet immediate obligations with highly liquid assets, followed by a weakening of that position.
- Quick Ratio Components
- Total quick assets increased from US$19,807 million in 2021 to US$23,971 million in 2023, before declining to US$17,846 million in 2025. Current liabilities decreased from US$35,194 million in 2021 to US$29,538 million in 2022, but subsequently increased to US$43,289 million in 2025. The combined effect of these movements contributed to the observed trend in the quick ratio.
- Year-over-Year Changes
- The most significant year-over-year change occurred between 2023 and 2024, with the quick ratio decreasing from 0.63 to 0.43. This decline coincided with a decrease in total quick assets and an increase in current liabilities. A similar, though less pronounced, decrease occurred between 2024 and 2025, with the quick ratio falling from 0.43 to 0.41, driven by continued increases in current liabilities and a slight decrease in quick assets.
The consistent decline in the quick ratio from 2022 through 2025 warrants further investigation. While the ratio remained above zero, indicating some capacity to cover immediate liabilities, the decreasing trend suggests a potential weakening in short-term financial flexibility.
Cash Ratio
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Cash and equivalents | ||||||
| Short-term investments | ||||||
| Total cash assets | ||||||
| Current liabilities | ||||||
| Liquidity Ratio | ||||||
| Cash ratio1 | ||||||
| Benchmarks | ||||||
| Cash Ratio, Competitors2 | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Cash Ratio, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Cash Ratio, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The cash ratio exhibited fluctuating behavior over the five-year period. Initially, the ratio demonstrated an increasing trend, followed by a significant decline in later years.
- Cash Ratio Trend
- The cash ratio began at 0.28 in 2021 and increased to 0.34 in 2023. This suggests an improving ability to cover current liabilities with immediately available cash during this timeframe. However, a substantial decrease is then observed, with the ratio falling to 0.14 in 2024 and further declining to 0.12 in 2025. This indicates a weakening short-term liquidity position.
- Total Cash Assets
- Total cash assets increased from US$9,830 million in 2021 to US$12,816 million in 2023, supporting the initial rise in the cash ratio. Subsequently, cash assets decreased significantly, reaching US$5,555 million in 2024 and US$5,257 million in 2025. This decline in cash holdings contributed to the later reduction in the cash ratio.
- Current Liabilities
- Current liabilities decreased from US$35,194 million in 2021 to US$29,538 million in 2022, potentially contributing to the initial improvement in the cash ratio. However, current liabilities then increased over the subsequent years, reaching US$43,289 million in 2025. This increase in short-term obligations, coupled with the declining cash balance, exacerbated the decrease in the cash ratio.
The combined effect of decreasing cash assets and increasing current liabilities resulted in a notable deterioration of the cash ratio from 2023 to 2025. This suggests a growing reliance on other liquid assets or financing options to meet short-term obligations.